Heart Valve Repair — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Heart valve repair is the surgical correction of a diseased or defective cardiac valve while preserving the patient's own valve tissue rather than replacing it with an artificial prosthesis. The heart has four valves — mitral, tricuspid, aortic, and pulmonary — each of which can develop regurgitation (leaking backward) or stenosis (restricting forward flow). Repair is the preferred surgical approach for mitral valve regurgitation (MR) and selected cases of tricuspid regurgitation because it preserves the native valve apparatus, maintains superior left ventricular geometry and contractile function, eliminates the risk of prosthesis-related complications (thromboembolism, endocarditis, structural degeneration), and avoids the need for lifelong anticoagulation required by mechanical valve prostheses. Expert cardiac surgical centres with dedicated valve repair programmes achieve repair rates exceeding 95% for degenerative mitral valve pathology (Barlow disease, fibroelastic deficiency), making replacement necessary only for the most complex or severely calcified valves. Minimally invasive approaches — right mini-thoracotomy (4–6 cm incision) and robotic-assisted repair — have largely replaced full median sternotomy at high-volume centres, producing equivalent durability with smaller incisions, reduced blood loss, shorter hospital stay, and faster recovery. Approximately 20,000 heart valve repair procedures are performed annually in the United Kingdom; globally, valve repair is the standard recommended over replacement wherever anatomically feasible.

Heart valve repair is indicated for significant valvular heart disease with evidence of haemodynamic impact, symptoms, or early myocardial dysfunction. Mitral valve repair is the gold-standard treatment for severe primary (degenerative) mitral regurgitation caused by posterior leaflet prolapse, anterior leaflet prolapse, bileaflet prolapse, or annular dilation secondary to dilated cardiomyopathy. Surgery is indicated when: the patient develops symptoms attributable to MR (exertional dyspnoea, reduced exercise tolerance); left ventricular ejection fraction declines below 60%; or the left ventricular end-systolic diameter exceeds 40 mm — even in the absence of symptoms — to prevent irreversible ventricular remodelling. Tricuspid valve repair with annuloplasty ring is performed at the time of left-sided valve surgery when significant functional tricuspid regurgitation is present (annular diameter over 40 mm or moderate–severe TR). Surgical repair of a bicuspid aortic valve is feasible in specialist centres for aortic regurgitation. Rheumatic valve disease, infective endocarditis with tissue destruction, and severely calcified degenerative valves are less amenable to repair; replacement may be necessary. Pre-operative assessment mandates transoesophageal echocardiography (TOE) for detailed leaflet anatomy, catheter angiography to exclude coronary artery disease, and cardiac CT for operative planning in complex cases.

Heart valve repair is performed under general anaesthesia. For open surgery via median sternotomy, the chest is opened with a longitudinal division of the sternum and pericardium. Cardiopulmonary bypass (CPB) is established by inserting venous cannulae into the right atrium and an arterial cannula into the ascending aorta; the heart is arrested using cold cardioplegic solution delivered into the aortic root. The left atrium is incised to expose the mitral valve. The cardiac surgeon inspects the valve leaflets, chordae tendineae, papillary muscles, and annulus systematically. Posterior leaflet repair technique: quadrangular or triangular resection removes the prolapsing segment of posterior leaflet; the leaflet edges are reapproximated with interrupted 3/0 and 4/0 monofilament sutures. If the leaflet tissue is sufficient, a sliding plasty is performed instead of resection. Annuloplasty ring placement is the cornerstone of all repairs: a rigid, semi-rigid, or flexible ring (Carpentier-Edwards, Medtronic Memo, St. Jude Tailor) is sutured around the mitral annulus with multiple interrupted 2/0 Ethibond sutures to resize and reshape the annulus to its normal saddle shape. Anterior leaflet prolapse is repaired with artificial Gore-Tex neo-chordae of calibrated length, replacing ruptured native chordae. Commissurotomy frees fused leaflet edges in rheumatic disease. A competence test is performed by filling the left ventricle with saline via a bulb syringe to check for residual regurgitation. Cardiopulmonary bypass is then weaned. Intraoperative transoesophageal echocardiography (TOE) immediately assesses repair quality — any residual regurgitation greater than mild triggers immediate re-arrest and further repair. Minimally invasive right mini-thoracotomy uses a 4–6 cm anterolateral chest incision with peripheral CPB (femoral vessels) and video or robotic visualisation of the valve; the technique has equivalent durability to sternotomy in experienced centres. Total operative time is 3–5 hours; CPB time is 60–120 minutes.

In high-volume, experienced cardiac surgical centres, mitral valve repair achieves durable repair in over 95% of degenerative (floppy) mitral valve cases — Barlow disease and fibroelastic deficiency. Ten-year freedom from reoperation is 85–92%, reflecting the durability of modern repair techniques combined with rigid annuloplasty rings. Compared with mitral valve replacement, repair provides: significantly better 10-year survival (meta-analysis demonstrates 3–7% absolute survival advantage); elimination of thromboembolic stroke risk from prosthetic valves (reducing stroke incidence by 60–70%); superior preservation of left ventricular geometry and ejection fraction; freedom from mandatory lifelong anticoagulation (avoiding the bleeding and thrombotic risks of warfarin therapy); and lower rates of prosthesis-related endocarditis (under 1% for repair versus 1–2% per year for prostheses). Minimally invasive repair via right mini-thoracotomy reduces post-operative atrial fibrillation rates (from 40% to 25–30%), transfusion requirements by approximately 30%, ICU stay by 0.5–1 days, hospital stay by 1–2 days, and produces substantially better cosmetic results with no longitudinal sternal wound. Rheumatic MR repair has lower durability (freedom from reoperation 65–75% at 10 years) due to ongoing rheumatic activity and progressive leaflet deformity, but still outperforms replacement in younger patients in developing nations.

Mortality for elective isolated mitral valve repair at high-volume centres is below 1% in patients under 70 years without significant comorbidities. Risk increases substantially with age over 75 years, impaired left ventricular function (EF below 40%), renal impairment, urgent or emergency surgery, and concomitant coronary artery bypass grafting. Intra-operative repair failure — residual moderate or severe MR on intraoperative TOE — occurs in 2–5% and requires immediate valve replacement in the same operation. Post-operative atrial fibrillation (AF) develops in 25–40% of patients, typically resolving within 6 weeks; warfarin and rhythm control are required until restoration of sinus rhythm. Stroke affects less than 2% of repair patients; risk is higher in patients with concomitant AF or aortic atherosclerosis. Reoperation for late repair failure (progressive MR from further chordal rupture, annuloplasty ring dehiscence, or leaflet perforation) occurs in 1–3% per year for complex repairs and 0.5–1% per year for standard posterior leaflet resections. Wound complications including deep sternal wound infection affect under 1% of sternotomy cases; wound infection risk is substantially lower with minimally invasive approaches. Permanent pacemaker implantation for heart block complicating surgery is required in approximately 1–3% of mitral valve procedures. Endocarditis of the repaired valve occurs at less than 0.5% per year — lower than prosthetic valve endocarditis rates.

After heart valve repair, patients are transferred to the cardiac surgical intensive care unit (ICU) where they are extubated within 4–8 hours of surgery in most uncomplicated cases. Epicardial pacing wires and a chest drain are removed on the first or second post-operative day. Patients sit out of bed on day 1 and walk short distances by day 2 with cardiac rehabilitation physiotherapy. An echocardiogram is performed before hospital discharge (typically day 5–8 for sternotomy, day 3–5 for minimally invasive approach) to confirm repair durability and establish a baseline for follow-up. Aspirin 75 mg daily is prescribed for 3 months post-repair to reduce thromboembolic risk during the healing period; patients with post-operative AF require anticoagulation with warfarin (target INR 2–3) or a direct oral anticoagulant until sinus rhythm is confirmed, or long-term if AF persists. Full sternal healing after sternotomy requires 6–8 weeks: no driving, no lifting over 5 kg, and no strenuous upper body activity during this period. Cardiac rehabilitation commences at 6–8 weeks — a structured programme of graduated exercise and lifestyle education that improves cardiovascular fitness, psychological well-being, and long-term outcomes. Return to desk work is at 6–8 weeks; physically demanding occupations require 10–12 weeks. Echocardiographic surveillance at 1 month, 6 months, and annually thereafter monitors for progressive regurgitation, annuloplasty ring position, and ventricular function.